Pacer Advisors
BBIO icon

Pacer Advisors’s BridgeBio Pharma BBIO Stock Holding History

Pacer Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,545
Closed -$39.1K – 2576
2024
Q2 		$39.1K Buy
1,545
+72
+5% +$1.97K ﹤0.01% 3277
2024
Q1 		$45.5K Buy
+1,473
New +$50.1K ﹤0.01% 3204
2021
Q2 		– Sell
-1,103
Closed -$68K – 1423
2021
Q1 		$68K Sell
1,103
-1,044
-49% -$68.3K ﹤0.01% 1386
2020
Q4 		$153K Sell
2,147
-1,518
-41% -$73.2K ﹤0.01% 1277
2020
Q3 		$138K Buy
+3,665
New +$115K ﹤0.01% 1220

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pacer Advisors's BBIO Position: Q3 2024 in Review

Pacer Advisors sold out of BridgeBio Pharma (BBIO) in Q3 2024, closing a stake of 1,545 shares — an estimated $39.1K sold.

Pacer Advisors first reported a position in BBIO in Q3 2020 and held it in 5 quarters. The position peaked at $153K in Q4 2020. 253 funds tracked by Wall St. Rank hold BBIO as of Q3 2024.

  • Pacer Advisors reported no remaining BridgeBio Pharma position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 1,545 BridgeBio Pharma shares in Q3 2024, an estimated $39.1K.
  • Pacer Advisors first reported a position in BridgeBio Pharma in Q3 2020 and held it in 5 quarters.
  • Pacer Advisors's BridgeBio Pharma position peaked at $153K in Q4 2020.
  • 253 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.